{"name":"Ruihua Xu","slug":"ruihua-xu","ticker":"","exchange":"","domain":"","description":"Ruihua Xu is a biotechnology company focused on developing innovative cancer therapies. The company's lead candidate is a combination therapy involving Tucidinostat (chidamide), a PD-1 inhibitor (Toripalimab), and Bevacizumab, currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxOQzhGMm1SdDNaYjU4aWctcmRCZnl5eHFGc1FscGh4amdrM2ltM1B0eGlneHQtLU1aaURXaEZsMmkxYTdtVEZGYTB1bno3SFVVQ1BBRnhzWnhpNUJvVWZxUjZwaTFwNkl0N2Q3TlBwNHR0bVpicTBkVW04R0RGRVhMWmI5S1kzbEVpNkR2bDBRQkNielF1Ymt0LTd0aV9RT1BYbzE5NEdhcms5UUtMbkZVWFhHa0hQdUtFRmQ2VWhFUEstdl9QazNpTWh5SEh0NGJNcktqUEpIMUJxUQ?oc=5","date":"2025-02-25","type":"pipeline","source":"BioPharma APAC","summary":"Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer - BioPharma APAC","headline":"Innovent’s Ipilimumab NDA Accepted by China’s NMPA with Priority Review for MSI-H/dMMR Colon Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOdmt1cy1nRU41eVdXT2xtZGhfZjlYUjhZNG9YaWVkZUZFWVhoSjNfbVhrdlpXTm9qVkFpUGVvUjg4dzRCdXB0aFVUazNEUnFzNjNuUHNULVpNdWpwSVRjMjI0QU9TRVVUUEJLNkh0cWJaN1lOT2NQMlhnU2lWSjVCZWhyVTlPb0tBbU9HbmxuejZPdVhhbmVXRFpHZFU5X2dIRzZrWUtCcy1QdGlxZGNaUGFXN1N6U2l3SVpxNXV6b0pXSUpRM05qY2Z1bU01UnFwVEVIdXFSYWthRlpk?oc=5","date":"2025-01-06","type":"regulatory","source":"BioPharma APAC","summary":"Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer - BioPharma APAC","headline":"Astellas Pharma Announces NMPA Approval of Zolbetuximab in China for Advanced Gastric and GEJ Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBfc0I0NDNGVDRJM3ZxMlhnMDhIdTJzdzRwNGtsQ0w3X3JLQW5yaVFVX0M0Zi1xcF9YR2JmdXBwblV0Z2hWRk1VRWpwNTN5STFYS2tZUG5oWUVJUGJRZ0Rz?oc=5","date":"2023-07-31","type":"trial","source":"nature.com","summary":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial - nature.com","headline":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQcEI2bVNreUFBLTNxVDk1V0JWa0tPLUM3MUcwV01rZ0w1TWY3R3JWbjlMSEtOWHUxS0RKWEd0NU9fUWRlcTBFaUlLdFpUczR3T1VadlA3MENDYlRrSnJPMGN6bVNfWEliYXpWdjlRZFlGVnQxR0x2ZEoxY0NrQmdxMnNuTGFuWHR3VWN0MmNlMGRYd2dCRk9MQTIzSGhGckNTNVlwbGlnZDRUZWhKQnpYbU1TX3o1V21lRlFrTEJDYlJWMHdFaXAzM29lRmlPSVh4Q2NJ?oc=5","date":"2023-04-25","type":"trial","source":"ascopost.com","summary":"GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset - ascopost.com","headline":"GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}